12/28/2020 7:33:16 AM
Zai Lab, Cullinan Oncology Collaborate For CLN-081 In China
12/1/2020 7:44:59 AM
Zai Lab Names Alan Sandler President, Head Of Global Development, Oncology
10/9/2020 9:06:30 AM
Zai Lab Reports Full Exercise Of Over-allotment Option
10/5/2020 7:41:07 AM
Zai Lab Announces First Patient Dosed In China In Global Phase 3 Study Of Retifanlimab In Patients With NSCLC
9/28/2020 7:36:02 AM
Zai Lab Announces Listing Of Its Ordinary Shares On Hong Kong Stock Exchange
9/22/2020 8:13:46 AM
Zai Lab Prices Hong Kong Secondary Listing Of 10.56 Mln New Ordinary Shares
9/16/2020 7:42:13 AM
Zai Lab Announces Launch Of Its Hong Kong Public Offering
9/10/2020 7:40:06 AM
Zai Lab: China NMPA Approves ZEJULA For First-Line Maintenance Treatment Of Ovarian Cancer
8/17/2020 7:35:34 AM
Zai Lab Appoints Ty Edmondson As Chief Legal Officer
8/4/2020 7:53:56 AM
Zai Lab: China's NMPA Granted Priority Review Status To NDA For Ripretinib
7/20/2020 7:40:23 AM
Zai Lab And Deciphera Pharma: China NMPA Accepts NDA For Ripretinib For Advanced Gastrointestinal Stromal Tumor
7/7/2020 7:40:34 AM
Turning Point Therapeutics And Zai Lab Announce License Agreement For Repotrectinib In Greater China
5/28/2020 7:51:42 AM
Zai Lab Announces NORA Study Meets All Primary And Secondary Endpoints
4/16/2020 7:42:10 AM
Zai Lab Announces China’s NMPA Grants Priority Review To SNDA For ZEJULA
4/16/2020 7:40:28 AM
Zai Lab Announces China's NMPA Grants Priority Review To SNDA For ZEJULA
4/8/2020 6:02:01 AM
Regeneron And Zai Lab Announce Regional Strategic Collaboration For REGN1979